Abgenix to begin Phase IIb psoriasis study of ABX-IL8

ABGX expects to begin this quarter placebo-controlled U.S. Phase IIb testing of its ABX-IL8 human monoclonal antibody against IL-8 to treat moderate-to-severe psoriasis. Efficacy end points in the 225...